Member Info for saxonaxe

https://www.fintech.finance/01-news/city-a-m-partners-with-global-micropayment-provider-satoshipay/

UPDATE FROM IMM

Good to hear from you

Yes we still have NDA’s in place with a number of potential licensing partners

We are working with our new joint brokers regarding a further analyst report

We have said in recent announcements that we are continuing with our proactive investor relations strategy which involves media interviews – as seen with Proactive, Vox Markets and Directors Talk – more to come

We will also update the market regularly on progress within MAP, and other programmes within our pipeline

We do not have control over the share price but believe with our ongoing IR strategy, and progress with MAP, a re-alignment of the share price will follow

Please keep in touch

Regards
Lisa

Lisa Baderoon
Head of Investor Relations
ImmuPharma PLC

I dont think that is what he is saying. I think you will find that is what you are suggesting. why wouldn't they treat the cohort of Lupus sufferers that will respond to treatment?

I suppose you would like them to treat people with measles or flu to see if it helped them?

We are now looking at Lupuzour down and dirty, doing its job, not in a synthetic test. It will stand or fall on its own merits as to how people react to the medication and for that reason alone I strongly believe in a positive outcome. As i mentioned earlier, we will be the last to know how well it has performed, because the moment any positive indication is seen, we will be taken out, at what price i dont know, but i think some of the old targets were somewhat ambitious, but they were, of course, assuming a positive Phase III and therefore a bidding war. Good luck to all in..

Morning all, my thoughts for what is worth, is that we are currently at the mercy of the market and traders until such time as we see some sort of reaction from the ongoing trails or we get bought out, and in both scenarios we will be the last to know and it will happen very quickly if we are taken. Question is, will you be in, or out?

RdR

so obviously the company Tim named is not one of the NDAs, and knowing that, he has in theory offered up competition to the NDAs, knowing that the named company would also be watching any MAP process..very interesting, and just my own thoughts on this...

Yes Johna58 but everything we read nowadays oints towards a relaxing of the regulations in every part of the world, for medicines and treatments like LUP, and this is what I am looking towards, real world tests real world results and an opportunity for sufferers to get a level of care that works, quote Barbie Manchester for example.Tim mentioned one specific company, quite deliberately in my opinion, that sucessfully used this process to get to market, and as such, they will be looking at any other company that follows this route, IMHO...

RdR

Dont forget the big C (China) as they are also watching with interest. the P140 platform may also come into play here too, dont forget that aspect of this drug..

Jonah, isnt this exactly what is going to happen in the MAP? from what i could get from Tims interview is that this will all be in the hands of the individuals physicians..

I can see your concerns. I think that within the timescale that IMM are looking at, the confidence is high that the real world results will be more than sufficient in a short period of time, especially in Europe, to project this to a worldwide market..and then who knows.

Yes I agree. What I would like to see is that in Q1 19 we see a couple of full remission patients, now that really would put the cat amongst the pigeons..I think that MAP is an excellent way for Lup to be seen in the real world and not in the hermetically sealed walls of a trial..

why would they need to wish and pray? the MAP would not be allowed if it were dangerous, nor would the extension. we have a 16%+ holding in another company and cash in the bank. The MAP As announced on 7 September 2018, agreement signed with a specialist provider to enter LupuzorTM into a 'Managed Access Programme'. whats not to like?

if you dont like it hunkymonkey go check out IRON

Liking this RNS alot..! let see where we finish today once the traders have their 10%

RdR

Yes, Stanford Capital Partners and Si Capital are now our joint brokers with Northland Capital replacing Bryan Garnier

We are currently updating the website

As clarification, Northlands are still writing research

Panmure, no longer part of our advisory team write independent research

We hope that Stanford Capital will commence writing on ImmuPharma in the near future

Many thanks
Lisa

Lisa Baderoon
Head of Investor Relations

I also found it interesting that Tim mentioned Merck (and he was very deliberate about it) during his appraisal of MAP program.

time will tell...

Seriously? you have nothing better to do than nit pick?

to all other posters on here, well done today for some thoughtful insight

So Darren, do you have any more pearls of wisdom? anything more to discuss? I think you have made your point, and is was really, just a negative point of view, with nothing to substantiate your comment

I dont see why they should have to report this just to satisfy you, as a possible non shareholder. you really are just a trouble maker really arent you. I asked Lisa at IMM about Bryan Garnier and she replied within minutes. I have also mentioned to her that it would be beneficial tidy up the webiste so that it is clear what is going on broker wise, after yesterdays announcement.